Costo E Impacto Presupuestal Del Tratamiento Del Cáncer De Púlmon De Celulas No Pequeñas Del Tipo Adenocarcinoma Con Grado Ecog 0,1,2 En Estadio Iv Con Mutación + (EGFR O ALK) Con Terapias Blanco En México

Abstract

the respective countries were elicited from local experts and clinical guidelines in addition to 1L> 2L BEV sequences obtained from the ML18147 trial. Results: When 1L> 2L BEV replaces sequences which include 1L anti-EGFR regimens, it results in an average potential cost reduction of 796